8-K: vTv Therapeutics Expands HPP737 Global Licensing Deal

vTv Therapeutics' subsidiary, vTv LLC, amended its license agreement with Newsoara Biopharma, expanding global rights for its PDE4 inhibitor HPP737 for an upfront payment of $20 million and potential milestones up to $115 million plus royalties.

Summary

• vTv Therapeutics LLC, a subsidiary of vTv Therapeutics Inc., entered into a Second Amendment to its License Agreement with Newsoara Biopharma Co., Ltd. on January 30, 2026.
• This amendment expands Newsoara's rights for the PDE4 inhibitor, HPP737, to include all countries of the world.
• Newsoara will pay an upfront fee of $20 million upon payment.
• The agreement includes potential development milestones of up to $50 million.
• Sales-related milestones could reach up to $65 million.
• vTv LLC will also receive royalties in the mid single digits, dependent on sales volumes.
• A previous amendment to the Original Agreement, entered into on May 31, 2018, became null and void in June 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, securing immediate cash and substantial future revenue potential through global expansion of a key asset, HPP737.

Positives

• Secured an immediate upfront payment of $20 million, providing a direct cash infusion.
• Expanded the licensing territory for HPP737 to a global scale, significantly increasing market potential.
• Established potential future revenue streams through development milestones up to $50 million and sales-related milestones up to $65 million.
• Introduced ongoing royalty payments in the mid single digits based on future sales volumes, offering long-term income potential.
• Replaced a previously voided amendment with a new, more comprehensive global agreement.

Future Outlook

The Second Amendment significantly expands the commercial potential for HPP737 by granting Newsoara global rights, which is expected to generate substantial future revenue through milestone payments and ongoing royalties, contingent on successful development and sales.

Management Comments

• Paul J. Sekhri, President and Chief Executive Officer of VTV THERAPEUTICS INC., duly caused this report to be signed on behalf of the registrant, indicating the company's formal entry into the Second Amendment to the License Agreement.

Industry Context

StockSavvy.ai notes that licensing agreements, particularly those involving global rights and significant milestone payments, are a common and crucial strategy for biopharmaceutical companies like vTv Therapeutics. These deals allow companies to monetize their intellectual property, share development risks, and access broader markets through established partners like Newsoara Biopharma, especially for assets like PDE4 inhibitors which have broad therapeutic potential.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to immediate cash inflow, significant future milestone payments, and long-term royalty streams from global market expansion.
• Employees: Potential for increased stability and resources for continued research and development efforts.
• Customers/Patients: Potential for HPP737 to reach a global patient population more effectively through Newsoara's expanded rights.

Next Steps

• The Company intends to file the Second Amendment with the SEC as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2025.

Key Dates

Recommendation

The expanded global licensing agreement for HPP737 with Newsoara Biopharma represents a significant positive catalyst. The immediate $20 million upfront payment, coupled with potential milestone payments up to $115 million and ongoing mid-single-digit royalties, provides a clear path to substantial future revenue. The global reach of the deal significantly enhances the asset's commercial potential and de-risks its development and commercialization by leveraging a partner. This agreement is a strong indicator of the value of vTv Therapeutics' pipeline and should be viewed very favorably by investors.

Keywords

vTv Therapeutics, Newsoara Biopharma, HPP737, PDE4 inhibitor, License Agreement, Biopharma, Pharmaceuticals, Drug Development, Global Rights, Milestone Payments, Royalties